0 results for 'Fish'
Court Orders Cost-Shifting for 'Needlessly Overbroad' Discovery
This Federal E-Discovery column by H. Christopher Boehning and Daniel J. Toal discusses a recent decision that brings renewed attention to the possibility of cost-shifting under Rule 26(c), and addresses when it may be appropriate.The FDA and COVID-19: Streamlined Processes and Enforcement
The FDA has taken steps to both accelerate the biotech and life sciences industry's work to test, diagnose and treat COVID-19 as well as rein in misguided or unscrupulous COVID-19 products.On the Move: Tracking the Ins and Outs of California Lawyers
New hires and promotions from across the California legal market.Judge Freeman Poised to Award Amazon Fees in Big Patent MDL
U.S. District Judge Beth Labson Freeman said she's "really very troubled" by the shifting theories patentee PersonalWeb Technologies pursued over the course of the case. But she sounded wary of awarding Amazon the entire $6.1 million it's seeking.'Cheeks v. Freeport Pancake House': Five Years Later
Today marks the five-year anniversary of Second Circuit's decision in Cheeks v. Freeport Pancake House. In the years since Cheeks was decided, the contours of what is permissible and impermissible in the settlement of FLSA claims have been developed by the district courts as they undertake "Cheeks" review of FLSA settlement agreements.Playing dead: Cashing in on insurance fraud
Faking death to escape debt or collect insurance might seem extreme, but how easy is it to do?Faking Own Death to Reap Insurance Benefits: A Guide
Faking death to escape debt or collect insurance might seem extreme, but how easy is it to do?Fish & Richardson to Host Hatch-Waxman Webinar
Fish & Richardson is scheduled to host a webinar titled "The Impact of Patent Term Extension on Litigation Under the Hatch-Waxman Act: A Look at the Federal Circuit's Recent Decision in Biogen v. Banner Life Scis."Novartis Agrees to Pay $678M for Illegal Kickbacks in 'Sham' Speaker Scheme
After nearly a decade of litigation, Novartis Pharmaceuticals Corp. (Novartis) has agreed to pay over $678 million in separate settlements to resolve claims that it systematically violated the federal False Claims Act and the Anti-Kickback Statute.You Received a Federal Grand Jury Subpoena—What Happens Next?
Practical guidance for individuals and companies to consider if served with a federal grand jury subpoena.Trending Stories
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
Document Review Challenges: Strategies for Law Firm Litigation Professionals in 2024
Brought to you by Integreon
Download Now
From Burnout to Breakthrough: How Technology Enhances Legal Wellness
Brought to you by Nuix
Download Now
The 2024 Benchmark of Ethical Culture Report
Brought to you by LRN
Download Now
State Lawmakers Targeting Plastic Pollution in 2024
Brought to you by LexisNexis®
Download Now